Endocrinology

GEROPHARM is in the TOP-3 on the Russian insulin market. The company produces insulins on a full-cycle basis - from substance to finished dosage form.

Main / Portfolio / Endocrinology

Own unique technology
Full cycle – from a substance to finished dosage form
Independence from foreign suppliers of raw stock
GEROPHARM insulin substance has been identified* as consistent with the requirements of European and American Pharmacopoeias.
Rinsulin substance is ahead of international standards in terms of degree of purification from impurities
Modern dosage forms: vials, cartridges, pen-injectors

* Independent certified laboratories: Proteome Factory AG Berlin, Prolytic GmbH Frankfurt am Main, Labor L+S AG

RinLis® (insulin lispro)

RinGlar® (insulin glargine)

RinLis® Mix 25 (insulin lispro biphasic 25)

Rinsulin® means reliable control and safety

Rinsulin® Mix 30/70 (insulin human)

RinFast® (insulin aspart)

RinFast® Mix 30 (insulin aspart binphasic)

Rinsulin® means reliable control and safety

Individual Pen-injector for insulin injections

Evodin® (evogliptin)

Medicinal product at the stage of development

Rinformin® long (metformin long)

Insulin Degludec

Medicinal product at the stage of development

Pipeline

Areas of development

Endocrinology

GEROPHARM is developing a full line of insulin bio analogues that are at different stages of studying.

Neurology
Orphan diseases

See also

Pharmacovigilance

GEROPHARM pays considerable attention to the regulation of drug safety. The company has the pharmacovigilance system which functions in accordance with the requirements of Russian and international regulatory authorities

Scientific Events

GEROPHARM pays considerable attention to the regulation of drug safety. Currently, the company has the pharmacovigilance system which functions in accordance with international requirements and regulatory requirements for the Russian Federation

Go up